Akums Drugs Reports Strong Q2 FY27 Consolidated Financial Results
Akums Drugs and Pharmaceuticals Ltd · Change in Management · 02 Nov 2026, 11:04 pm
Akums Drugs Reports Strong Q2 FY27 Consolidated Financial Results Akums Drugs and Pharmaceuticals reported a consolidated revenue from operations of ₹13,423.87 million for the quarter ended 30th Sep'26, up 31.9% YoY from ₹10,175.30 million. Net profit attributable to owners surged 176.7% YoY to ₹1,128.51 million compared to ₹407.83 million in the prior-year period. Operating performance was led by its CDMO segment, which generated ₹11,148.66 million in external revenue. The company also fully utilized 100% of its ₹6,800.00 million IPO proceeds and appointed Sanjay Kumar as Senior Management Personnel effective 2nd Nov'26.
Original exchange filing (PDF)
More announcements from Akums Drugs and Pharmaceuticals Ltd
- Intimation of Schedule of the Investors/Analysts Meet · 10 Nov 2026
- Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026 · 05 Nov 2026
- Audio recording of Earning/ Quarterly Conference Call · 03 Nov 2026
- Newspaper Publication · 03 Nov 2026
- Final Report of CRISIL Ratings Limited, Monitoring Agency · 03 Nov 2026
- Q2 FY 2026-27 - Investor Presentation · 02 Nov 2026
- Press Release · 02 Nov 2026
- Akums Drugs and Pharmaceuticals Limited has informed the Exchange about change in Management · 02 Nov 2026
